共 50 条
- [1] Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled studyLANCET RESPIRATORY MEDICINE, 2017, 5 (10): : 785 - 794Ghofrani, Hossein-ArdeschirSimonneau, GeraldD'Armini, Andrea M.Fedullo, PeterHoward, Luke S.Jais, XavierJenkins, David P.Jing, Zhi-ChengMadani, Michael M.Martin, NicolasMayer, EckhardPapadakis, KellyRichard, DominikKim, Nick H.
- [2] Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1) results from the multicentre, phase 2, randomised, double-blind, placebo-controlled studyLANCET RESPIRATORY MEDICINE, 2024, 12 (04): : e21 - e30Ghofrani, Hossein -ArdeschirSimonneau, GeraldD'Armini, Andrea M.Fedullo, PeterHoward, Luke S.Jais, XavierJenkins, David P.Jing, Zhi-ChengMadani, Michael M.Martin, NicolasMayer, EckhardPapadakis, KellyRichard, DominikKim, Nick H.
- [3] Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT studyEUROPEAN RESPIRATORY JOURNAL, 2017, 50Simonneau, GeraldJing, Zhi C.D'Armini, Andrea M.Fedullo, PeterHoward, LukeJais, XavierJenkins, David P.Kim, Nick H.Madani, MichaelMartin, NicholasMayer, EckhardPapadakis, KellyRichard, DominikGhofrani, Hossein A.
- [4] Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trialLANCET RESPIRATORY MEDICINE, 2019, 7 (07): : 594 - 604Sitbon, OlivierBosch, JaumeCottreel, EmmanuelleCsonka, Denesde Groote, PascalHoeper, Marius M.Kim, Nick H.Martin, NicolasSavale, LaurentKrowka, Michael
- [5] RETRACTION: Statement of Retraction: Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study (Retraction of Vol 23, Pg 245, 2017)INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2022, 26 (04) : 417 - 417Wang, JingLiu, Xi-FangFeng, ChongBao, QuanFu, Hong-Ran
- [6] Thymosin α1 treatment of chronic hepatitis B:: results of a phase III multicentre, randomized, double-blind and placebo-controlled studyJOURNAL OF VIRAL HEPATITIS, 1999, 6 (05) : 397 - 403Mutchnick, MGLindsay, KLSchiff, ERCummings, GDAppelman, HDPeleman, RRSilva, MRoach, KCSimmons, FMilstein, SGordon, SCEhrinpreis, MN
- [7] Selexipag for Chronic Thromboembolic Pulmonary Hypertension in Japanese Patients - A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase II Study -CIRCULATION JOURNAL, 2020, 84 (10) : 1866 - 1874Tanabe, NobuhiroFukuda, KeiichiMatsubara, HiromiNakanishi, NorifumiTahara, NobuhiroIkeda, SatoshiKishi, TakuyaSatoh, ToruHirata, Ken-ichiInoue, TeruoKimura, HiroshiOkano, YoshiakiOkazaki, OsamuSata, MasatakaTsujino, IchizoUeno, ShuichiYamada, NorikazuYao, AtsushiKuriyama, Takayuki
- [8] RETRACTION: Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double-blind, randomized, placebo-controlled trial (vol 29, pg 354, 2023) (Retraction of Vol 29, Pg 354, 2023)CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (03)Abdallah, M. S.Mosalam, E. M.Hassan, A.
- [9] TOCILIZUMAB (TCZ) IS NOT EFFECTIVE FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS (AS): RESULTS OF A PHASE 2, INTERNATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 110 - 111Sieper, J.Porter-Brown, B.Thompson, L.Harari, O.Dougados, M.